Publication:
Cardiac troponin T for early detection of cardiotoxicity in breast cancer patients treated with epirubicin

Simple item page
dc.contributor.authorDEDE, FUAT
dc.contributor.authorsErdim, Refik; Celiker, Aydin; Gemici, Goekmen; Tokay, Sena; Uelfer, Goezde; Dede, Fuat; Turhal, Serdar; Oktay, Ahmet
dc.date.accessioned2022-03-12T17:46:48Z
dc.date.available2022-03-12T17:46:48Z
dc.date.issued2009
dc.description.abstractThe aim of the study was to investigate the role of cTnT for the prediction of long term cardiac dysfunction after epirubicin-containing adjuvant chemotherapy for breast cancer. The study group comprised of 45 patients (all female; mean age 48 +/- 8 years), treated with epirubicin-containing adjuvant chemotherapy for stage 2 and stage 3 breast cancer. Patients received either 4 cycles of cyclophosphamide plus epirubicin (90 mg/m(2)) (n=23; stage 2 breast cancer) or 6 cycles of cyclophosphamide plus epirubicin (75 mg/m(2)) plus fluorouracil (n=18; stage 3 breast cancer). Venous blood samples were drawn, before and 72 hours after, every cycle of chemotherapy for the measurement of cTnT. Cardiac assessment was carried out at baseline and 1 year after chemotherapy by clinical evaluation, electrocardiography, radio-nuclide ventriculography (RNV) and transthoracic echocardiography. All patients remained free of clinical heart failure during the study period. In 26 patients (63%), cTnT was elevated after chemotherapy. Mean left ventricular ejection fraction, assessed by RNV at baseline and one year after chemotherapy, were 61 +/- 8% and 56 +/- 7% (p < 0.0001). The sensitivity and specifity of cTnT for the detection of left ventricular systolic dysfunction at one year were 69% and 39% respectively. Echocardiographic examinations at baseline and one year after chemotherapy revealed a significant decrease in E/A ratio from 1.15 +/- 0.3 to 0.9 +/- 0.2 in cTnT positive patients, suggesting diastolic dysfunction. In conclusion, elevated serum cTnT levels after epirubicin-containing adjuvant chemotherapy for stage 2 and stage 3 breast cancer, predict future cardiac dysfunction with moderate sensitivity and poor specificity.
dc.identifier.doi10.2478/s11536-008-0093-z
dc.identifier.eissn1644-3640
dc.identifier.issn1895-1058
dc.identifier.urihttps://hdl.handle.net/11424/229557
dc.identifier.wosWOS:000267669000011
dc.language.isoeng
dc.publisherDE GRUYTER POLAND SP ZOO
dc.relation.ispartofCENTRAL EUROPEAN JOURNAL OF MEDICINE
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBreast cancer
dc.subjectChemotherapy
dc.subjectEpirubicin
dc.subjectCardiotoxicity
dc.subjectcTnT
dc.subjectANTHRACYCLINE-INDUCED CARDIOTOXICITY
dc.subjectADJUVANT CHEMOTHERAPY
dc.subjectDIASTOLIC FUNCTION
dc.subjectCHILDHOOD-CANCER
dc.subjectLEUKEMIA
dc.subjectSURVIVORS
dc.titleCardiac troponin T for early detection of cardiotoxicity in breast cancer patients treated with epirubicin
dc.typearticle
dspace.entity.typePublication
local.avesis.idc9de863e-f635-4400-b01f-361554e5d87f
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.journal.numberofpages4
oaire.citation.endPage330
oaire.citation.issue3
oaire.citation.startPage327
oaire.citation.titleCENTRAL EUROPEAN JOURNAL OF MEDICINE
oaire.citation.volume4
relation.isAuthorOfPublicationdbe5967c-c66d-4e50-97c6-0334cb93f7da
relation.isAuthorOfPublication.latestForDiscoverydbe5967c-c66d-4e50-97c6-0334cb93f7da

Files

Collections

Research Outputs